Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients
Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study
研究概览
详细说明
Chronic kidney disease (CKD) is a major socio-economic and healthcare problem and represents a significant global public health challenge. The burden of disease is disproportionately higher in low- and middle-income countries. As per the Global Burden of Disease (GBD) 2023 estimates, approximately 788 million people were affected by CKD globally, with a global age-adjusted prevalence of 14.2% among adults aged 20 years and older. CKD has a significant global burden, affecting over 9% of the world population and was directly responsible for 1.2 million deaths worldwide in 2017 alone.
Chronic kidney disease is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m² persisting for three months or more, irrespective of the underlying cause. It represents a state of progressive loss of kidney function, ultimately resulting in the need for renal replacement therapy in the form of dialysis or kidney transplantation. Kidney damage refers to pathological abnormalities detected by imaging or renal biopsy, abnormalities in urinary sediment, or increased urinary albumin excretion rates.
The leading cause of CKD is diabetes mellitus, followed by hypertension and glomerular diseases. The prevalence of individuals with CKD due to type 1 diabetes has continued to increase globally, rising by 21.7% between 2007 and 2017 and reaching approximately 3.2 million individuals in 2017. These individuals are at increased risk of cardiovascular complications, and nearly 25-30% progress to kidney failure. Irrespective of the initial nephropathy, once a critical mass of nephrons is lost, kidney disease generally follows a progressive course toward advanced stages, resulting in increased morbidity and mortality.
The burden of CKD arises not only from the management of end-stage renal disease but also from complications related to CKD and its associated comorbidities. There are effective strategies to reduce the rate of CKD progression and improve patient outcomes; therefore, the need for therapies aimed at slowing disease progression is critical.
Periodontal bacteria, which cause chronic inflammation and the breakdown of tooth-supporting structures, are the cause of periodontal disease, a chronic infectious oral illness. One of the most prevalent oral illnesses worldwide is periodontitis, affecting almost 20-50% of the global population in varying degrees, and the percentage rises with advancing age. In India, 51% of people had periodontal disease overall. Periodontal disease is implicated as an independent risk factor for CKD. Periodontitis is defined as an inflammatory disease of the supporting tissues of the teeth caused by specific microorganisms or groups of microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone, with periodontal pocket formation, gingival recession, or both.
Chronic kidney disease and periodontal disease are strongly interconnected through shared inflammatory, metabolic, and immune pathways. Periodontal disease has been implicated as an independent risk factor for CKD and may also act as a risk factor for several acquired systemic diseases. The bidirectional relationship between periodontal disease and systemic conditions highlights the importance of oral health assessment in medically compromised populations.
Inflammation is defined as the tissue's biological response to harmful stimuli such as pathogens or irritants. Chronic inflammation and elevated inflammatory markers play a crucial role in the progression and adverse outcomes of CKD. Evidence from previous studies demonstrates that declining renal function is associated with increased levels of circulating inflammatory cytokines. Several investigations have proposed that chronic dental infections, particularly periodontal disease, contribute significantly to the systemic inflammatory burden observed in CKD patients. The pathophysiological concept of periodontitis involves the systemic dissemination of inflammatory mediators such as CRP, IL-6, and tumor necrosis factor-α (TNF-α), either due to local bacterial infection causing periodontal tissue destruction or through the systemic spread of periodontal pathogens and their endotoxins. Periodontitis, being a chronic inflammatory condition, may significantly amplify the existing systemic inflammatory burden in CKD, thereby contributing to disease progression and associated complications.
Periodontal infections worsen the systemic inflammatory status, leading to poor renal outcomes in CKD patients. Improving oral health care through non-surgical periodontal therapy may improve the systemic inflammatory status and renal function. Various studies demonstrated elevated levels of CRP and IL-6 in patients with periodontal disease and their significant reduction following non-surgical periodontal therapy (NSPT). These findings suggest that periodontal intervention may play a role in modulating systemic inflammation.
In the Indian context, where the prevalence of diabetes and CKD is increasing rapidly and access to dialysis remains limited for a large proportion of the population, strategies aimed at delaying progression to end-stage renal disease are of particular importance. Oral health is often neglected in medically compromised individuals, and periodontal disease frequently remains untreated. Addressing periodontal health may therefore represent an overlooked yet impactful component of comprehensive CKD care.
Thus, the present non-randomized controlled study is designed to evaluate the effectiveness of subgingival instrumentation in delaying the progression to end-stage renal disease or the initiation of dialysis among diabetic patients with stage IV chronic kidney disease. By assessing both periodontal and renal parameters over a defined follow-up period of 12 months, this study aims to generate evidence supporting the integration of periodontal care into the comprehensive management of diabetic CKD patients.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Gurleen Kaur, MDS
- 电话号码:+91 9354031553
- 邮箱:drgurleenphd@gmail.com
研究联系人备份
- 姓名:Vipul Yadav, MDS
- 电话号码:+91 8826363961
- 邮箱:vipulyadavv.97@gmail.com
学习地点
-
-
Haryana
-
Rohtak、Haryana、印度、124001
- Post Graduate Institute of Dental Sciences , Rohtak
-
接触:
- Gurleen Kaur, MDS
- 电话号码:9354031553
- 邮箱:drgurleenphd@gmail.com
-
接触:
- Vipul Yadav, MDS
- 电话号码:8826363961
- 邮箱:vipulyadavv.97@gmail.com
-
首席研究员:
- Gurleen Kaur, MDS
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Patients aged 40-70 years.
- Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.
- Diagnosed with Stage IV or V (eGFR between 15-20 mL/min/1.73m²).
- Not undergoing dialysis.
- Presence of ≥20 natural teeth.
- Diagnosed with moderate (Stage II) (as per 2017 World Workshop classification) (Interdental CAL at site of greatest loss >2mm but <5 mm in ≥ 2 non-adjacent teeth).
- Willingness to provide written informed consent.
Exclusion Criteria:
- Patients already undergoing haemodialysis or renal transplantation.
- Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.
- HbA1c level >8 %.
- Any Periodontal therapy within past 6 months.
- Immunocompromised patients.
- Any history of tobacco use.
- Pregnant or lactating women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention Group
Intervention Group participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI).
|
Participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI).
Participants will receive basic oral hygiene instructions
|
|
有源比较器:Comparator Group
Control group participants will receive basic oral hygiene instructions
|
Participants will receive basic oral hygiene instructions
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Estimated glomerular filtration rate
大体时间:Estimated glomerular filtration rate (eGFR) estimation will be performed at 3,6,9 and 12 months.
|
Renal function will be assessed by calculating the Estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
The CKD-EPI equation incorporates serum creatinine concentration, age, and sex to provide an estimate of kidney function expressed as mL/min/1.73
m².
|
Estimated glomerular filtration rate (eGFR) estimation will be performed at 3,6,9 and 12 months.
|
|
Soluble Urokinase Plasminogen Activator Receptor(suPAR)
大体时间:The estimation of soluble urokinase plasminogen activator receptor (suPAR) will be done at baseline and 12 months.
|
The estimation of soluble urokinase plasminogen activator receptor (suPAR) in plasma will be performed using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA).
The assay employs a sandwich ELISA technique, where suPAR in the plasma sample binds to specific antibodies immobilized on the microplate.
Following incubation and washing steps, an enzyme-conjugated detection antibody and substrate solution will be added.
The enzymatic reaction will produce a measurable colour change proportional to the concentration of suPAR.
The absorbance will be recorded at 450 nm using an ELISA microplate reader, and the concentration was calculated using a standard curve.
|
The estimation of soluble urokinase plasminogen activator receptor (suPAR) will be done at baseline and 12 months.
|
|
Periodontal markers
大体时间:Measurement will be done at Baseline, 3, 6, 9 and 12 months.
|
Different periodontal markers including Pocket Probing Depth(PPD), Clinical Attachment Loss(CAL), Bleeding on Probing(BOP), Calculus Component of Oral Hygiene Index will be estimated. Measurement will be done at six sites (mesiobuccal, mid-buccal, distobuccal, mesiolingual/palatal, mid-lingual/palatal, and distolingual/palatal) on all maxillary and mandibular teeth. PPD will be measured from the gingival margin to the base of the pocket, while CAL will be measured from the CEJ to the base of the pocket/sulcus. All the measurements will be rounded to the nearest millimeter and will be recorded using a Williams probe. For BOP, WHO Probe will be used and bleeding areas will be documented at six sites per tooth. |
Measurement will be done at Baseline, 3, 6, 9 and 12 months.
|
|
Renal parameters including Serum creatinine, Serum albumin and Serum urea
大体时间:Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed at baseline,3,6,9 and 12 months.
|
Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed. Serum creatinine levels will be estimated using the Jaffe's kinetic method / enzymatic colorimetric method on an automated biochemistry analyser. The results will be expressed in milligrams per decilitre (mg/dL). Serum albumin levels will be measured using the bromocresol green (BCG) dye-binding method. The results will be expressed in grams per decilitre (g/dL). The normal reference range for serum albumin will be considered as 3.5-5.0 g/dL. Serum urea will be estimated using the urease-glutamate dehydrogenase (GLDH) method / diacetyl monoxime method on an automated analyser. The values will be expressed in mg/dL, with a normal reference range of 15-45 mg/dL. |
Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed at baseline,3,6,9 and 12 months.
|
|
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis to dialysis.
大体时间:Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be estimated from baseline till 12 month follow up.
|
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be calculated.
|
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be estimated from baseline till 12 month follow up.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
High-sensitivity C-reactive protein (hs-CRP)
大体时间:Change in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to 3,6,9 and 12 months will be checked.
|
The concentration of high-sensitivity C-reactive protein (hs-CRP) in plasma will be estimated using a high-sensitivity immunoturbidimetric assay with a commercially available diagnostic kit.
Plasma sample will be added to hs-CRP reagent containing anti-CRP antibodies.
The mixture will be incubated to allow antigen-antibody complex formation.
The change in absorbance will be measured using an automated biochemical analyzer.
hs-CRP concentration will be determined using a calibration curve.
|
Change in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to 3,6,9 and 12 months will be checked.
|
|
Glycated Haemoglobin (HbA1c) levels
大体时间:Glycated haemoglobin (HbA1c) levels assessment will be done at baseline, 3, 6, 9 and 12 months.
|
Glycated haemoglobin (HbA1c) levels will be measured to assess long-term glycaemic control among study participants.
Venous blood samples will be collected and analyzed using standardized laboratory methods.
HbA1c reflects the average blood glucose concentration over the preceding 2-3 months and will be expressed as a percentage (%).
The measured HbA1c values will be used to evaluate participants' glycaemic status.
Assessment will be performed at baseline, 3, 6, 9 and 12 months.
|
Glycated haemoglobin (HbA1c) levels assessment will be done at baseline, 3, 6, 9 and 12 months.
|
合作者和调查者
调查人员
- 研究主任:Vipul Yadav, MDS、Professor, Department of Public Health Dentistry, Post Graduate Institute of Dental Sciences Rohtak
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Gurleen2676
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.